What question did this study set out to answer?

To evaluate the impact of mineralocorticoid receptor antagonists on cardiovascular events in dialysis patients.

May 2, 2026

Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.

Key Points

To evaluate the impact of mineralocorticoid receptor antagonists on cardiovascular events in dialysis patients.
Conducted a systematic review and meta-analysis of 14 randomized trials.
Focus on cardiovascular outcomes and adverse events associated with MRAs in dialysis patients.
MRAs significantly reduce the incidence of nonfatal cardiovascular events in dialysis patients (p<0.001).
Severe hyperkalemia, gynecomastia, and breast pain are noted risks associated with MRA use.

Abstract

< 0.001). In conclusion, MRAs can reduce the incidence of nonfatal cardiovascular events in dialysis patients; however, clinicians also need to be mindful of the risks of severe hyperkalemia as well as gynecomastia and breast pain in men when prescribing them.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Yifan Zhu

Juan Li

Zhongping Huang

Actions

Institutions

Huzhou University

Third People's Hospital of Huzhou

Jiangxi Pingxiang People's Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Mineralocorticoid receptor antagonists in dialysis patients after ACHIEVE and ALCHEMIST: updated systematic review and meta-analysis of 14 randomized trials.

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider